Compile Data Set for Download or QSAR
Report error Found 99 Enz. Inhib. hit(s) with all data for entry = 921
TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298513(US10125111, Compound 3012)
Affinity DataEC50:  3.20nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298506(US10125111, Compound 3005)
Affinity DataEC50:  5nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298551(US10125111, Compound 4007)
Affinity DataEC50:  5.30nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298572(US10125111, Compound 4028)
Affinity DataEC50:  5.60nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298511(US10125111, Compound 3010)
Affinity DataEC50:  5.60nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298508(US10125111, Compound 3007)
Affinity DataEC50:  5.70nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298573(US10125111, Compound 4029)
Affinity DataEC50:  5.90nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298518(US10125111, Compound 3017)
Affinity DataEC50:  6.30nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298559(US10125111, Compound 4015)
Affinity DataEC50:  7.5nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298590(US10125111, Compound 9003)
Affinity DataEC50:  7.60nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298566(US10125111, Compound 4022)
Affinity DataEC50:  7.70nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298556(US10125111, Compound 4012)
Affinity DataEC50:  8nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298547(US10125111, Compound 4003)
Affinity DataEC50:  9.30nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298521(US10125111, Compound 3020)
Affinity DataEC50:  9.40nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298578(US10125111, Compound 5006)
Affinity DataEC50:  9.40nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298581(US10125111, Compound 6003)
Affinity DataEC50:  9.5nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298563(US10125111, Compound 4019)
Affinity DataEC50:  9.80nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298591(US10125111, Compound 9004)
Affinity DataEC50:  10.6nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298535(US10125111, Compound 3034)
Affinity DataEC50:  11.7nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298502(US10125111, Compound 2005)
Affinity DataEC50:  14.7nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298541(US10125111, Compound 3040)
Affinity DataEC50:  41.3nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298496(US10125111, Compound 1001)
Affinity DataEC50:  57.8nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298592(US10125111, Compound 9005)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298593(US10125111, Compound 9006)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298594(US10125111, Compound 9007)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298503(US10125111, Compound 2006)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298504(US10125111, Compound 3003)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298505(US10125111, Compound 3004)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298507(BDBM298517 | US10125111, Compound 3006)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298509(US10125111, Compound 3008)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298497(US10125111, Compound 1002)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298498(US10125111, Compound 2001)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298500(US10125111, Compound 2003)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298501(US10125111, Compound 2004)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298519(US10125111, Compound 3018)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298520(US10125111, Compound 3019)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298522(US10125111, Compound 3021)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298523(US10125111, Compound 3022)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298524(US10125111, Compound 3023)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298525(US10125111, Compound 3024)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298510(US10125111, Compound 3009)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298512(US10125111, Compound 3011)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298514(US10125111, Compound 3013)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298515(US10125111, Compound 3014)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298516(US10125111, Compound 3015)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298507(BDBM298517 | US10125111, Compound 3006)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298534(US10125111, Compound 3033)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298539(US10125111, Compound 3038)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298526(US10125111, Compound 3025)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM298528(US10125111, Compound 3027)
Affinity DataEC50: <100nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
US Patent

Displayed 1 to 50 (of 99 total ) | Next | Last >>
Jump to: